

Steve Sisolak
Governor
Richard Whitley, MS
Director



DEPARTMENT OF
HEALTH AND HUMAN SERVICES
Division of Health Care Financing and Policy
Helping people. It's who we are and what we do.



Suzanne Bierman, JD, MPH
Administrator

NOTICE OF PUBLIC MEETING – SILVER STATE SCRIPTS BOARD

Date of Posting: February 16, 2021

Date of Meeting: Thursday, March 25, 2021 at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Silver State Scripts Board.

Place of Meeting: [Microsoft Teams](#)

OR

https://teams.microsoft.com/l/meetup-join/19%3ameeting_OTI4NjJmYzYtNWVmYS00YmUyLTk1NTUtMTg1ZmRiZTk4YzE2%40thread.v2/0?context=%7b%22id%22%3a%22db05faca-c82a-4b9d-b9c5-0f64b6755421%22%2c%22oid%22%3a%2242971ee7-a94c-4957-b200-48069e3c9add%22%7d

Out of deference to Declaration of Emergency Directive 006 from the State of Nevada Executive Department signed by Governor Sisolak on March 22, 2020 & Emergency Directive 003 signed March 20, 2020, a physical location will not be open to the public for attendance at this time.

Note: *If at any time during the meeting an individual who has been named on the agenda or has an item specifically regarding them included on the agenda is unable to participate because of technical or other difficulties, please email Tanya Benitez at tbenitez@dhcfnv.gov and note at what time the difficulty started so that matters pertaining specifically to their participation may be continued to a future agenda if needed or otherwise addressed.*

Meeting Audio Information: Phone: (952) 222-7450
Event: 106 959 100#

[Please place your phone on mute unless providing public comment.]

Closed Executive Session – 1:00 PM

Open Session/Public Meeting – will begin upon completion of the Closed Executive Session

AGENDA

- 1. Call to Order and Roll Call**
- 2. Public Comment on Any Matter on the Agenda** *(Owing to the lack of a physical location for this meeting, public comment is encouraged to be submitted in advance so that it may be included in meeting materials and given attention. No action may be taken upon a matter raised through public comment unless the matter itself has been specifically included on an agenda as an action item. Please provide your name in any comment for record keeping purposes. You may submit comments in writing via e-mail to (rxinfo@dncfp.nv.gov). There may be opportunity to take public comment via telephone, but phone participants should disconnect their call and re-join if they must take another call. Do not place your phone on hold or you may disrupt the meeting for other participants. This guidance applies for all periods of public comment referenced further in the agenda, such as those related to clinical presentations.)*
- 3. Administrative**
 - a. **For Possible Action:** Review and Approve Meeting Minutes from January 21, 2021.
 - b. Status Update by the DHCFP.
 - c. Presentation and discussion of updated Silver State Scripts Board bylaws.
- 4. Proposed New Drug Classes**
 - a. **For Possible Action:** Discussion and possible adoption of Cardiovascular Agents - Antilipemics - PCSK9 Inhibitors.
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- 5. Established Drug Classes Being Reviewed Due to the Release of New Drugs**
 - a. **For Possible Action:** Discussion and possible adoption of Hormones and Hormone Modifiers - Antidiabetic Agents - Inulin (vials, Pens and Inhaled).
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.

- iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- b. **For Possible Action:** Discussion and possible adoption of Gastrointestinal Agents - Antiemetics - Serotonin-receptor antagonists/combo and Dopamine Antagonists.
- i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

6. Established Drug Classes

- a. **For Possible Action:** Discussion and possible adoption of Cardiovascular Agents - Antihypertensive Agents - Beta-Blockers.
- i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- b. **For Possible Action:** Discussion and possible adoption of Genitourinary Agents - Bladder Antispasmodics.
- i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

7. OptumRx Reports: New Drugs to Market and New Line Extensions

8. Closing Discussion

- a. Public comments on any subject. (*Owing to the lack of a physical location for this meeting, public comment is encouraged to be submitted in advance so that it may be included in meeting materials and given attention. No action may be taken upon a matter raised through public comment unless the matter itself has been specifically included on an agenda as an action item. Please provide your name in any comment for record keeping purposes. You may submit comments in writing via e-mail to (rxinfo@dncfp.nv.gov). There*

may be opportunity to take public comment via telephone, but phone participants should disconnect their call and re-join if they must take another call. Do not place your phone on hold or you may disrupt the meeting for other participants. Public comments may be related to topics on the agenda or matters related to other topics per NRS 241.020(3)(3)(II).)

- b. Date and location of the next meeting.
 - i. Discussion of the time of the next meeting.
- c. Adjournment.

PLEASE NOTE: Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to three minutes and written comments are encouraged if possible.

This notice and agenda have been posted online at <http://dhcfnv.gov> and <http://notice.nv.gov> as well as Carson City, Las Vegas, and Reno central offices for the Division of Health Care Financing and Policy. E-mail notice has been made to such individuals as have requested notice of meetings (to request notifications please contact tbenitez@dhcfnv.gov, or at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Tanya Benitez at (775) 684-3730). At this time, in deference to Emergency Directive 006 dated March 22, 2020 and related directives which have discouraged certain in-person activities, notice has not been posted at other physical locations.

If you require a physical copy of supporting material for the public meeting, please contact tbenitez@dhcfnv.gov, or at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Tanya Benitez at (775) 684-3730). Supporting material will also be posted online as referenced above.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.

Note: We are pleased to make reasonable accommodations for members of the public with a disability and wish to participate. If accommodated arrangements are necessary, notify the Division of Health Care Financing and Policy as soon as possible and at least ten days in advance of the meeting, by e-mail at tbenitez@dhcfnv.gov in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Tanya Benitez at (775) 684-3730.

Per Nevada Governor Sisolak's Declaration of Emergency Directive 006; Subsection 3: The requirements contained in NRS 241.020 (4) (a) that public notice agendas be posted at physical locations within the State of Nevada are suspended.

Per Nevada Governor Sisolak's Declaration of Emergency Directive 006; Subsection 4: Public bodies must still comply with requirements in NRS 241.020 (4)(b) and NRS 241.020 (4)(c) that public notice agendas be posted to Nevada's notice website and the public body's website, if it maintains one along with providing a copy to any person who has requested one via U.S. mail or electronic mail.

February 16, 2021

Page 5

Per Nevada Governor Sisolak's Declaration of Emergency Directive 006; Subsection 5: The requirement contained in NRS 241.020 (3)(c) that physical locations be available for the public to receive supporting material for public meetings is suspended.

Per Nevada Governor Sisolak's Declaration of Emergency Directive 006; Subsection 6: If a public body holds a meeting and does not provide a physical location where supporting material is available to the public, the public body must provide on its public notice agenda the name and contact information for the person designated by the public body from whom a member of the public may request supporting material electronically and must post supporting material to the public body's website, if it maintains one.
